The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.
Earlier this year, patients treated by an AI chatbot for some common mental health challenges got better. This was significant because the patients were part of the first randomized and controlled trial for this type of AI intervention.
